top of page

Current Grant Support

NIH-NINDS R21NS135430-01 – Regulation of Schwann Cell Mitochondria Homeostasis in Painful Peripheral Neuropathy. PIs: Campana and Pekkurnaz. Major goals: The foundation for this research project is the discovery that the low-density lipoprotein receptor-related protein (LRP1) in Schwann cells (SCs) dramatically alters mitochondrial properties. 2023- 2025

Veterans Administration I01BX006386-01 –Targeting LRP1 in Neuroinflammation and Neuropathic Pain. PI: Campana. Major goals: To determine whether molecular mediators, generated by injured peripheral nerves, bind the low-density lipoprotein receptor related protein (LRP1) and regulate Schwann cell physiology and painful peripheral neuropathies. 2024-2028

NIH-NCI-NINDS R43CA268700 – Pre-clinical Validation of Phase II Peptide Agonists to Treat and Prevent Chemotherapy Induced Peripheral Neuropathy. PIs: Campana and Gelber. Major goals: To identify second generation small molecules from Alpha-1-Anti-Trypsin peptides that are efficacious in treating chemotherapy induced peripheral neuropathy. 2022-2023

Department of Defense W81XWH 22-1-0722 –Treating Oral Cancer Pain with LRP1 Agonists. PIs: Campana and Ye. Major goals: To determine whether LRP1 modulators can reduce tumor size and thus, reduce facial pain associated with oral cancer. 2022-2025

Veterans Administration 101 RX003363-01A1 –Targeting Schwann cell exosomes for treating neuropathic pain. PI: Campana. Major goals: To isolate Schwann cell derived small extracellular vesicles (pSC EVs) from plasma of rodent with neuropathic pain. Cargo of neuropathic pSC EVs is investigated. 2020-2024

NIH-NIDCR R01DE029493 –Schwann Cell Activation in Oral Cancer Invasion and Neuropathic Pain. PI: Ye, Co-I: Campana. Major goals: To determine whether Schwann cells contribute to oral cancer pain and regulate the extracellular environment. 2020-2025

bottom of page